The World Looks To Scientific Studies To Explain Zantac's NDMA Contamination

Experts agree that NDMA is a deadly carcinogen, but questions remain on how Zantac became contaminated

Tuesday, March 16, 2021 - Thousands of former Zantac users have filed suit that alleges ranitidine naturally degrades and forms dangerously high levels of NDMA. Exactly how this occurs remains a mystery. Some scientists think that ranitidine is unstable and susceptible to high drug storage temperatures while others think that the contamination occurs at the source of manufacturing in China and India, countries with lax environmental regulations. Another theory postulates that NDMA forms when ranitidine interacts with nitrates in the stomach. To date, there is no definitive explanation for how ranitidine becomes carcinogenic. Over 15 million people were taking Zantac in 2020 before the FDA stepped in and issued a recall. Zantac users are left not only looking for another way to solve their heartburn and acid reflux problems but also are worried that they may have developed cancer from taking Zantac regularly and for many years. There may be millions of Zantac cancer victims unknowingly walking around since cancer has a ten-year or longer latency period. The world is looking to scientific studies for the answers. Zantac cancer victims have allegedly developed stomach, bladder, esophageal, colon, prostate, breast, and other forms of cancer from using the heartburn medicine. Many are suing Sanofi because of failing to warn them of the cancer risks allegedly due to taking the drug. If you or a loved one have taken Zantac and developed cancer, you may want to speak with a Zantac cancer lawyer as you may be eligible to file a claim.

Legal Examiner published their thoughts on a recent study that looked to see if Zantac users had a higher than normal risk of developing cancer. LE wrote, "According to researchers publishing their findings in the scientific journal Cancers, patients who used Zantac may have an increased risk of several types of cancers, including esophageal, stomach, and colorectal cancer," and that, " a 2000 study that discovered ranitidine use was associated with a 2.4-fold increased risk for the combined outcome of stomach/esophageal cancer."

The study's author, Gerald McGwin, Department of Epidemiology, School of Public Health, the University of Alabama at Birmingham wrote in his study titled: "The Association between Ranitidine Use and Gastrointestinal Cancers," "The results of the current study provided direct support for the assertion that NDMA contaminated ranitidine is associated with the occurrence of gastrointestinal cancer. This assertion was bolstered by an abundance of evidence demonstrating that NDMA exposure is associated with an increased risk of cancer in humans and animals. Observational studies show a relationship between dietary and occupational exposure to NDMA and specific cancers, principally to the gastrointestinal system. " At the center of the cancer scare is the carcinogen N-nitrosodimethylamine (NDMA). NDMA has been classified as probably carcinogenic by the World Health Organization and has been used by scientists to produce cancer tumors in lab test animals. NDMA occurs naturally in groundwater and soil and is found in higher concentrations around industrial manufacturing facilities.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.